DelveInsight’s “HER2-Positive Breast Cancer – Market Insight, Epidemiology And Market Forecast – 2032” report provides comprehensive insights into the historical and forecasted HER2-positive breast cancer epidemiological trends, current treatment paradigms, and emerging therapies across the 7MM, which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report further analyzes market drivers, barriers, and unmet medical needs to identify the most promising opportunities within the evolving HER2-positive breast cancer treatment landscape.
The US currently dominates the HER2-positive breast cancer market, accounting for USD 1.6 billion in 2023. Furthermore, the total market size in EU4 and the UK exceeded USD 800 million in 2023, with projections indicating substantial growth through 2032.
Download the HER2-positive breast cancer market report to understand which factors are driving the HER2-positive breast cancer therapeutic market @ HER2-positive breast cancer Market Trends.
HER2-positive breast cancer, which accounts for approximately 15-20% of all breast cancers, represents a historically aggressive subtype with increased risk of recurrence and metastasis if not properly treated. According to DelveInsight’s epidemiological analysis, total HER2-positive breast cancer incident cases in the 7MM were more than 100K in 2023, with this figure expected to rise throughout the forecast period (2019-2032). The HR+/HER2+ breast cancer cases were highest in the US, with approximately 44K cases, while Germany led among EU4 and UK countries with around 11K cases. Furthermore, prevalence varies by age, with most HER2-positive breast cancer cases occurring in people between 40 and 60 in the US.
Discover evolving trends in the HER2-positive breast cancer patient pool forecasts @ HER2-positive breast cancer Epidemiology Analysis.
The current HER2-positive breast cancer treatment landscape has evolved significantly with the development of targeted therapies that have transformed patient outcomes. Monoclonal antibodies like HERCEPTIN (Roche and Genentech) and PERJETA (Roche) form the backbone of treatment.
The development of antibody-drug conjugates (ADCs), such as ENHERTU (Daiichi Sankyo and AstraZeneca) and KADCYLA (Roche), represents a breakthrough in treating metastatic breast cancer, particularly for HER2-positive subtypes. KADCYLA was the first ADC to gain FDA approval for breast cancer treatment, establishing itself as the standard of care in the second-line setting. In a trial in 2021, ENHERTU demonstrated superior efficacy compared to KADCYLA, establishing itself as the new standard of care in previously treated HER2-positive metastatic breast cancer.
Additionally, kinase inhibitors such as NERLYNX from Puma Biotechnology (NASDAQ: PBYI) and newer entries like MARGENZA from MacroGenics Inc. (NASDAQ: MGNX) provide options for patients who have progressed on earlier therapies.
The pipeline for HER2-positive metastatic breast cancer is expanding, with several promising candidates in late-stage development. Ambrx’s ARX788, an anti-HER2 antibody-drug conjugate (ADC), has shown statistically significant results in its prespecified interim primary efficacy endpoint during the ACE-Breast-02 trial, demonstrating greater progression-free survival compared to the active control. Additionally, Zanidatamab, an investigational bispecific antibody developed by Zymeworks and Jazz Pharmaceuticals, has produced encouraging results in combination with palbociclib and fulvestrant for HER2-positive solid tumors in an ongoing Phase II trial.
In the next 6 to 8 months, several clinical trials are expected to report results that could significantly impact current medical practices. One of the most anticipated is the DESTINY-Breast05 trial (NCT04622319), which is examining the use of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in the adjuvant setting for patients with HER2-positive breast cancer who have residual disease following neoadjuvant therapy. If successful, T-DXd could potentially replace the current standard treatment, ado-trastuzumab emtansine (T-DM1), offering a superior alternative.
Recent FDA approvals continue to reshape treatment paradigms. In April 2024, the FDA approved ENHERTU as the first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors. Further, in January 2025, ENHERTU was approved as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer.
Additionally, in February 2025, Shanghai Henlius Biotech announced that the FDA accepted its biologics license application for HLX11, a biosimilar to Roche’s PERJETA, potentially expanding treatment access and affordability.
Discover recent advancements in the HER2-positive breast cancer treatment landscape @ HER2-positive breast cancer Recent Developments.
Despite significant advancements, substantial challenges persist in the HER2-positive breast cancer treatment landscape. Brain metastases affect up to 50% of patients with metastatic HER2-positive breast cancer, significantly impacting quality of life and outcomes. Additionally, acquired resistance to current therapies remains a significant obstacle, necessitating novel approaches and rational combination strategies to overcome resistance mechanisms and extend survival for patients with advanced disease.
Looking ahead, the HER2-positive breast cancer market is positioned for continued growth through 2032, driven by biomarker-guided precision medicine approaches, innovative drug delivery systems, and rational combination regimens. The integration of technologies for real-time monitoring of treatment response and resistance development is anticipated to optimize treatment sequencing and maximize clinical outcomes for patients with this aggressive breast cancer subtype.
Table of Contents
1. Key Insights
2. Executive Summary of HER2-positive Breast Cancer
3. Competitive Intelligence Analysis for HER2-positive Breast Cancer
4. HER2-positive Breast Cancer: Market Overview at a Glance
5. HER2-positive Breast Cancer: Disease Background and Overview
6. Patient Journey
7. HER2-positive Breast Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. HER2-positive Breast Cancer Unmet Needs
10. Key Endpoints of HER2-positive Breast Cancer Treatment
11. HER2-positive Breast Cancer Marketed Products
12. HER2-positive Breast Cancer Emerging Therapies
13. HER2-positive Breast Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of HER2-positive Breast Cancer
17. KOL Views
18. HER2-positive Breast Cancer Market Drivers
19. HER2-positive Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
HER2-Positive Breast Cancer Pipeline Insight
HER2-positive breast cancer pipeline insight provides comprehensive insights about the HER2-positive breast cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the HER2-positive breast cancer companies, including Prestige BioPharma, Jiangsu HengRui Medicine Co., Ltd., Zymeworks Inc., Shanghai EXUMA Biotechnology, ORIC Pharmaceuticals, Formosa Pharmaceuticals, EirGenix, ExpreS2ion Biotechnologies, Theratechnologies, Byondis, Tanvex Biopharma, Roche, Alphamab, Biocad, Shanghai Henlius Biotech, Novartis Pharmaceuticals, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., and Zydus Cadila, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
